Chronic ventricular arrhythmias: comparative drug effectiveness and toxicity.
D000319:Adrenergic beta-Antagonists / Q000009:adverse effects / Q000627:therapeutic use; D000813:Anilides / Q000009:adverse effects / Q000627:therapeutic use; D000889:Anti-Arrhythmia Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D001073:Aprindine / Q000009:adverse effects / Q000627:therapeutic use; D001145:Arrhythmias, Cardiac / Q000188:drug therapy*; D004206:Disopyramide / Q000009:adverse effects / Q000627:therapeutic use; D006352:Heart Ventricles; D006801:Humans; D008297:Male; D010672:Phenytoin / Q000009:adverse effects / Q000627:therapeutic use; D011342:Procainamide / Q000009:adverse effects / Q000627:therapeutic use; D011802:Quinidine / Q000009:adverse effects / Q000627:therapeutic use; D016677:Tocainide
D000319:Adrenergic beta-Antagonists; D000813:Anilides; D000889:Anti-Arrhythmia Agents; D016677:Tocainide; D001073:Aprindine; D010672:Phenytoin; D004206:Disopyramide; D011802:Quinidine; D011342:Procainamide